Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp (MARE)
Primary Purpose
Hypertension, Blood Pressure
Status
Completed
Phase
Phase 2
Locations
Finland
Study Type
Interventional
Intervention
Marealis Refined Peptide Concentrate
Marealis Refined Peptide Concentrate
Marealis Refined Peptide Concentrate
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring randomized double-blind placebo-controlled study, peptide concentrate, Coldwater Shrimp, antihypertensive effect, mild hypertension, moderate hypertension, blood pressure
Eligibility Criteria
Inclusion Criteria:
- mild or moderate hypertension (systolic blood pressure 130 - 160 mmHg and diastolic blood pressure ≤ 100 mmHg)
- age 30 - 75 years
- body weight ≥ 60 kg
- stable body weight
- use of effective contraception in women of childbearing potential
Exclusion Criteria:
- body mass index ≥ 35
- antihypertensive drug treatment, regular high dose NSAID treatment and the use of cyclosporine or tacrolimus
- diabetes (type 1 and 2)
- anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid function, clinically significant biochemistry, any other clinically significant hematology and/or biochemistry at the investigator's discretion
- cardiovascular disease (myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening) including stroke and congestive heart failure
- secondary hypertension history of cancer or malignant disease within the past five years
- any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subjects
- fish and other seafood allergies, citrus allergy, multiple food allergies
- alcohol abuse
- smokers and tobacco/snuff/nicotine users
- consumption of food supplements targeted to blood pressure lowering within 30 days before randomization
- pregnant and lactating mothers, women, planning for pregnancy during the study
- participation in clinical trials 30 days prior to this study and participation in other clinical intervention
Sites / Locations
- Oy Foodfiles Ltd
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Refined peptide concentrate, 1200 mg
Refined peptide concentrate, 2 x 600 mg
Refined peptide concentrate, 0 mg
Arm Description
Refined peptide concentrate, 1 200 mg, once a day
Refined peptide concentrate, 600 mg, twice a day
Outcomes
Primary Outcome Measures
change in systolic blood pressure
change from baseline after 8 weeks of treatment in systolic office blood pressure
Secondary Outcome Measures
change in diastolic blood pressure
change from baseline after 8 weeks of treatment in diastolic blood pressure
mean systolic blood pressure
mean diastolic blood pressure
change in systolic blood pressure
diastolic blood pressure
diastolic blood pressure
mean heart rate
mean fasting plasma glucose concentration
mean fasting plasma lipids concentration
plasma total cholesterol, HDL-cholesterol, LDL-cholesterol and total triglycerides concentration, respectively
mean serum C-reactive protein
blood count
plasma glutamyltransferase
plasma creatinine
plasma sodium concentration
plasma potassium concentration
adverse events
change in systolic blood pressure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01583582
Brief Title
Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp
Acronym
MARE
Official Title
Assessment on Antihypertensive Effect and Safety of Bioactive Peptides Derived From Coldwater Shrimp (Pandalus Borealis) in Healthy Subjects With Mild or Moderate Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Marealis AS
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this proof of concept study is to find out the efficacy of Marealis Refined Peptide Concentrate (RPC) from Coldwater Shrimp (Pandalus borealis) containing ACE-inhibiting peptides on blood pressure in subjects with mild or moderate hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Blood Pressure
Keywords
randomized double-blind placebo-controlled study, peptide concentrate, Coldwater Shrimp, antihypertensive effect, mild hypertension, moderate hypertension, blood pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
74 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Refined peptide concentrate, 1200 mg
Arm Type
Experimental
Arm Description
Refined peptide concentrate, 1 200 mg, once a day
Arm Title
Refined peptide concentrate, 2 x 600 mg
Arm Type
Experimental
Arm Description
Refined peptide concentrate, 600 mg, twice a day
Arm Title
Refined peptide concentrate, 0 mg
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Marealis Refined Peptide Concentrate
Intervention Description
1200 mg per os, once a day, 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Marealis Refined Peptide Concentrate
Intervention Description
600 mg per os, twice a day, 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Marealis Refined Peptide Concentrate
Intervention Description
0 mg per os, daily, 8 weeks
Primary Outcome Measure Information:
Title
change in systolic blood pressure
Description
change from baseline after 8 weeks of treatment in systolic office blood pressure
Time Frame
from baseline after 8 weeks of treatment
Secondary Outcome Measure Information:
Title
change in diastolic blood pressure
Description
change from baseline after 8 weeks of treatment in diastolic blood pressure
Time Frame
from baseline after 8 weeks of treatment
Title
mean systolic blood pressure
Time Frame
at the end of a 8-week treatment
Title
mean diastolic blood pressure
Time Frame
at the end of a 8-week treatment
Title
change in systolic blood pressure
Time Frame
from baseline after 4 weeks treatment
Title
diastolic blood pressure
Time Frame
from baseline after 4 weeks treatment
Title
diastolic blood pressure
Time Frame
from baseline after 2 weeks treatment
Title
mean heart rate
Time Frame
at the end of a 8-week treatment
Title
mean fasting plasma glucose concentration
Time Frame
at the end of a 8-week treatment
Title
mean fasting plasma lipids concentration
Description
plasma total cholesterol, HDL-cholesterol, LDL-cholesterol and total triglycerides concentration, respectively
Time Frame
at the end of a 8 week treatment
Title
mean serum C-reactive protein
Time Frame
at the end of a 8-week treatment
Title
blood count
Time Frame
at the end of a 8-week treatment
Title
plasma glutamyltransferase
Time Frame
at the end of a 8-week treatment
Title
plasma creatinine
Time Frame
at the end of a 8-week treatment
Title
plasma sodium concentration
Time Frame
at the end of a 8-week treatment
Title
plasma potassium concentration
Time Frame
at the end of a 8-week treatment
Title
adverse events
Time Frame
during the 8-week treatment
Title
change in systolic blood pressure
Time Frame
from the baseline after 2 weeks treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
mild or moderate hypertension (systolic blood pressure 130 - 160 mmHg and diastolic blood pressure ≤ 100 mmHg)
age 30 - 75 years
body weight ≥ 60 kg
stable body weight
use of effective contraception in women of childbearing potential
Exclusion Criteria:
body mass index ≥ 35
antihypertensive drug treatment, regular high dose NSAID treatment and the use of cyclosporine or tacrolimus
diabetes (type 1 and 2)
anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid function, clinically significant biochemistry, any other clinically significant hematology and/or biochemistry at the investigator's discretion
cardiovascular disease (myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening) including stroke and congestive heart failure
secondary hypertension history of cancer or malignant disease within the past five years
any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subjects
fish and other seafood allergies, citrus allergy, multiple food allergies
alcohol abuse
smokers and tobacco/snuff/nicotine users
consumption of food supplements targeted to blood pressure lowering within 30 days before randomization
pregnant and lactating mothers, women, planning for pregnancy during the study
participation in clinical trials 30 days prior to this study and participation in other clinical intervention
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Essi S Sarkkinen, Ph.D
Organizational Affiliation
Oy Foodfiles Ltd
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Sakari A Nieminen, MD
Organizational Affiliation
Oy Foodfiles Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oy Foodfiles Ltd
City
Kuopio
ZIP/Postal Code
70210
Country
Finland
12. IPD Sharing Statement
Learn more about this trial
Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp
We'll reach out to this number within 24 hrs